Synjardy

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
27-09-2023
Valmisteyhteenveto Valmisteyhteenveto (SPC)
27-09-2023

Aktiivinen ainesosa:

empagliflozin, metformin

Saatavilla:

Boehringer Ingelheim

ATC-koodi:

A10BD20

INN (Kansainvälinen yleisnimi):

empagliflozin, metformin

Terapeuttinen ryhmä:

Drugs used in diabetes

Terapeuttinen alue:

Diabetes Mellitus, Type 2

Käyttöaiheet:

Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

Tuoteyhteenveto:

Revision: 26

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2015-05-27

Pakkausseloste

                                66
B. PACKAGE LEAFLET
67
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SYNJARDY 5 MG/850 MG FILM-COATED TABLETS
SYNJARDY 5 MG/1,000 MG FILM-COATED TABLETS
SYNJARDY 12.5 MG/850 MG FILM-COATED TABLETS
SYNJARDY 12.5 MG/1,000 MG FILM-COATED TABLETS
empagliflozin/metformin hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Synjardy is and what it is used for
2.
What you need to know before you take Synjardy
3.
How to take Synjardy
4.
Possible side effects
5.
How to store Synjardy
6.
Contents of the pack and other information
1.
WHAT SYNJARDY IS AND WHAT IT IS USED FOR
WHAT SYNJARDY IS
Synjardy contains two active substances empagliflozin and metformin.
Each belongs to a group of
medicines called “oral anti-diabetics”. These are medicines taken
by mouth to treat type 2 diabetes.
WHAT IS TYPE 2 DIABETES?
Type 2 diabetes is a disease that comes from both your genes and your
lifestyle. If you have type 2
diabetes, your pancreas does not make enough insulin to control the
level of glucose in your blood,
and your body is unable to use its own insulin effectively. This
results in high levels of glucose in your
blood which can lead to medical problems like heart disease, kidney
disease, blindness, and poor
circulation in your limbs.
HOW SYNJARDY WORKS
Empagliflozin belongs to a group of medicines called sodium glucose
co-transporter-2 (SGLT2)
inhibitors. It works by blocking the SGLT2 protein in your kidneys.
This causes blood sugar (glucose)
to be removed in your urine. Metformin
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Synjardy 5 mg/850 mg film-coated tablets
Synjardy 5 mg/1,000 mg film-coated tablets
Synjardy 12.5 mg/850 mg film-coated tablets
Synjardy 12.5 mg/1,000 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Synjardy 5 mg/850 mg film-coated tablets
Each tablet contains 5 mg empagliflozin and 850 mg metformin
hydrochloride.
Synjardy 5 mg/1,000 mg film-coated tablets
Each tablet contains 5 mg empagliflozin and 1,000 mg metformin
hydrochloride.
Synjardy 12.5 mg/850 mg film-coated tablets
Each tablet contains 12.5 mg empagliflozin and 850 mg metformin
hydrochloride.
Synjardy 12.5 mg/1,000 mg film-coated tablets
Each tablet contains 12.5 mg empagliflozin and 1,000 mg metformin
hydrochloride.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Synjardy 5 mg/850 mg film-coated tablets
Yellowish white, oval, biconvex film coated tablets debossed with
“S5” and the Boehringer Ingelheim
logo on one side and “850” on the other side (tablet length: 19.2
mm, tablet width: 9.4 mm).
Synjardy 5 mg/1,000 mg film-coated tablets
Brownish yellow, oval, biconvex film coated tablets debossed with
“S5” and the Boehringer
Ingelheim logo on one side and “1000” on the other side (tablet
length: 21.1 mm, tablet width:
9.7 mm).
Synjardy 12.5 mg/850 mg film-coated tablets
Pinkish white, oval, biconvex film coated tablets debossed with
“S12” and the Boehringer Ingelheim
logo on one side and “850” on the other side (tablet length: 19.2
mm, tablet width: 9.4 mm).
Synjardy 12.5 mg/1,000 mg film-coated tablets
Dark brownish purple, oval, biconvex film coated tablets debossed with
“S12” and the Boehringer
Ingelheim logo on one side and “1000” on the other side (tablet
length: 21.1 mm, tablet width:
9.7 mm).
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Synjardy is indicated for the treatment of adults with type 2 diabetes
mellitus as an adjunct to diet and
exercise:

i
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto bulgaria 27-09-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 05-07-2017
Pakkausseloste Pakkausseloste espanja 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto espanja 27-09-2023
Pakkausseloste Pakkausseloste tšekki 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto tšekki 27-09-2023
Pakkausseloste Pakkausseloste tanska 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto tanska 27-09-2023
Pakkausseloste Pakkausseloste saksa 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto saksa 27-09-2023
Pakkausseloste Pakkausseloste viro 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto viro 27-09-2023
Pakkausseloste Pakkausseloste kreikka 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto kreikka 27-09-2023
Pakkausseloste Pakkausseloste ranska 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto ranska 27-09-2023
Pakkausseloste Pakkausseloste italia 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto italia 27-09-2023
Pakkausseloste Pakkausseloste latvia 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto latvia 27-09-2023
Pakkausseloste Pakkausseloste liettua 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto liettua 27-09-2023
Pakkausseloste Pakkausseloste unkari 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto unkari 27-09-2023
Pakkausseloste Pakkausseloste malta 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto malta 27-09-2023
Pakkausseloste Pakkausseloste hollanti 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto hollanti 27-09-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 05-07-2017
Pakkausseloste Pakkausseloste puola 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto puola 27-09-2023
Pakkausseloste Pakkausseloste portugali 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto portugali 27-09-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 05-07-2017
Pakkausseloste Pakkausseloste romania 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto romania 27-09-2023
Pakkausseloste Pakkausseloste slovakki 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto slovakki 27-09-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 05-07-2017
Pakkausseloste Pakkausseloste sloveeni 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto sloveeni 27-09-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 05-07-2017
Pakkausseloste Pakkausseloste suomi 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto suomi 27-09-2023
Pakkausseloste Pakkausseloste ruotsi 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto ruotsi 27-09-2023
Pakkausseloste Pakkausseloste norja 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto norja 27-09-2023
Pakkausseloste Pakkausseloste islanti 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto islanti 27-09-2023
Pakkausseloste Pakkausseloste kroatia 27-09-2023
Valmisteyhteenveto Valmisteyhteenveto kroatia 27-09-2023

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia